| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | 10.4B | 171.16 | 19.79 | 6.12% | -8.86% | -9.31% | 12.96% | 1.51 |
| ACADACADIA Pharmaceuticals Inc. | 4.49B | 26.53 | 19.51 | 31.85% | 24.94% | 28.47% | 3.5% | 0.07 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.82B | 22.96 | 17.53 | 23.49% | 37.63% | 23.64% | 8.48% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.1B | 36.41 | 14.51 | 22.8% | 22.48% | 22.23% | 10.43% | 0.28 |
| ALKSAlkermes plc | 5.15B | 31.22 | 14.39 | -6.36% | 22.27% | 19.55% | 7.87% | 0.05 |
| PRTCPureTech Health plc | 463.31M | 19.17 | 9.59 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 540.89M | 21.38 | -1.20 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 361.97M | 2.13 | -1.39 | -178.79% | 0.01 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 1.76M | 3.93M | 3.53M | 2.52M | 2.23M | 5.21M |
| Revenue Growth % | - | - | - | 1.23% | -0.1% | -0.29% | -0.12% | 1.34% |
| Cost of Goods Sold | 0 | 1.56M | 3.4M | 201 | 151 | 19.84M | 7.59M | 7.22M |
| COGS % of Revenue | - | - | 1.93% | 0% | 0% | 7.86% | 3.4% | 1.39% |
| Gross Profit | 0 | -1.56M | -1.64M | 3.93M | 3.53M | -17.31M | -5.36M | -2.01M |
| Gross Margin % | - | - | -0.93% | 1% | 1% | -6.86% | -2.4% | -0.39% |
| Gross Profit Growth % | - | - | -0.05% | 3.4% | -0.1% | -5.9% | 0.69% | 0.62% |
| Operating Expenses | 146.69K | -600K | 6.93M | 5.54M | 23.4M | 6.91M | 5.36M | 4.72M |
| OpEx % of Revenue | - | - | 3.93% | 1.41% | 6.63% | 2.74% | 2.4% | 0.91% |
| Selling, General & Admin | 146.69K | 0 | 6.93M | 1.15M | 18.71M | 6.91M | 5.36M | 4.72M |
| SG&A % of Revenue | - | - | 3.93% | 0.29% | 5.3% | 2.74% | 2.4% | 0.91% |
| Research & Development | 0 | 0 | 3.4M | 4.39M | 4.69M | 19.84M | 7.59M | 7.22M |
| R&D % of Revenue | - | - | 1.93% | 1.12% | 1.33% | 7.86% | 3.4% | 1.39% |
| Other Operating Expenses | 0 | 0 | -3.4M | 0 | 0 | -19.84M | -7.59M | -7.22M |
| Operating Income | -147K | -959K | -8.57M | -1.61M | -19.87M | -24.22M | -10.72M | -6.73M |
| Operating Margin % | - | - | -4.86% | -0.41% | -5.63% | -9.6% | -4.8% | -1.29% |
| Operating Income Growth % | - | -5.52% | -7.93% | 0.81% | -11.32% | -0.22% | 0.56% | 0.37% |
| EBITDA | -27.55K | 2.68M | -8.57M | -1.61M | -19.87M | -24.22M | -10.72M | -6.73M |
| EBITDA Margin % | - | - | -4.86% | -0.41% | -5.63% | -9.6% | -4.8% | -1.29% |
| EBITDA Growth % | - | 98.11% | -4.2% | 0.81% | -11.32% | -0.22% | 0.56% | 0.37% |
| D&A (Non-Cash Add-back) | 0 | 0 | 201 | 201 | 151 | 151 | -3 | 4 |
| EBIT | -27.55K | 2.68M | -8.57M | 834.62K | -25.93M | -24.22M | -10.72M | -6.73M |
| Net Interest Income | 0 | 0 | 4.25M | -276K | 1.92M | 1.14M | -354K | -1.29M |
| Interest Income | 0 | 3.63M | 4.25M | 719.65K | 3.21M | 1.25M | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 995.5K | 1.29M | 109.53K | 353.94K | 1.29M |
| Other Income/Expense | 119.14K | 3.63M | -1.53M | 1.45M | -9.28M | 14.41K | 91.91K | -1.26M |
| Pretax Income | -27.56K | 2.68M | -10.1M | -160.88K | -29.15M | -24.21M | -10.63M | -7.99M |
| Pretax Margin % | - | - | -5.73% | -0.04% | -8.25% | -9.59% | -4.76% | -1.53% |
| Income Tax | 3.63K | 553.92K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.13% | -0.5% | 1% | -0.35% | 1% | 1% | 1% | 1% |
| Net Income | -31.19K | -1.34M | -10.1M | 56.77K | -29.08M | -24.17M | -10.61M | -7.99M |
| Net Margin % | - | - | -5.73% | 0.01% | -8.24% | -9.58% | -4.76% | -1.53% |
| Net Income Growth % | - | -42.05% | -6.52% | 1.01% | -513.31% | 0.17% | 0.56% | 0.25% |
| Net Income (Continuing) | -31.19K | 2.12M | -10.1M | -160.88K | -29.15M | -24.21M | -10.63M | -7.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | -217.63K | -279.81K | -315.21K | -328.41K | -328.48K |
| EPS (Diluted) | -0.01 | -0.22 | 0.24 | 0.56 | -355.68 | -139.44 | -4.69 | -4.57 |
| EPS Growth % | - | - | 2.09% | 1.33% | -636.14% | 0.61% | 0.97% | 0.03% |
| EPS (Basic) | -0.01 | -0.22 | 0.24 | 0.56 | -355.68 | -139.44 | -4.69 | -4.57 |
| Diluted Shares Outstanding | 5.98M | 6.01M | 6.09M | 6.37M | 84.02K | 179.93K | 2.26M | 1.75M |
| Basic Shares Outstanding | 5.98M | 6.01M | 6.09M | 4.46M | 84.02K | 179.93K | 2.26M | 1.75M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.31M | 1.92M | 618.59K | 347.88K | 15.66M | 5.3M | 2.29M | 5.34M |
| Cash & Short-Term Investments | 2.09M | 1.66M | 341.54K | 194.21K | 12.26M | 3.15M | 1.12M | 3.5M |
| Cash Only | 2.09M | 1.66M | 341.54K | 194.21K | 12.26M | 3.15M | 1.12M | 3.5M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 170.53K | 173.55K | 0 | 441.72K | 276.82K | 97.56K | 124.11K |
| Days Sales Outstanding | - | - | 35.91 | - | 45.66 | 40.04 | 15.96 | 8.7 |
| Inventory | 0 | 0 | 0 | 0 | -441.72K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 68.81K | 23.54K | 2.59M | 1.33M | 18K | 18K |
| Total Non-Current Assets | 200.12M | 202.92M | 5.35K | 3.93K | 754.76K | 585.88K | 419.22K | 252.55K |
| Property, Plant & Equipment | 0 | 0 | 351 | 151 | 24.72B | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | 5025.53x | 26034.50x | 0.00x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 200.12M | 202.92M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 5K | 3.78K | -24.72B | 585.88K | 419.22K | 252.55K |
| Total Assets | 202.43M | 204.83M | 623.94K | 351.81K | 16.42M | 5.89M | 2.71M | 5.6M |
| Asset Turnover | - | - | 2.83x | 11.17x | 0.22x | 0.43x | 0.82x | 0.93x |
| Asset Growth % | - | 0.01% | -1% | -0.44% | 45.67% | -0.64% | -0.54% | 1.07% |
| Total Current Liabilities | 156.24K | 437.89K | 7.3M | 7.01M | 16.48M | 9.46M | 3.33M | 2.21M |
| Accounts Payable | 0 | 0 | 540.78K | 1.72M | 301.1K | 2.94M | 1.94M | 1.36M |
| Days Payables Outstanding | - | - | 58.01 | 1000K | 727.83K | 54.17 | 93.14 | 68.62 |
| Short-Term Debt | 0 | 0 | 2.62M | 4.25M | 12.75M | 4.27M | 854.7K | 301.66K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 159.05K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 152.6K | 437.89K | 2.93M | 670.26K | 0 | 0 | 0 | 0 |
| Current Ratio | 14.77x | 4.38x | 0.08x | 0.05x | 0.95x | 0.56x | 0.69x | 2.42x |
| Quick Ratio | 14.77x | 4.38x | 0.08x | 0.05x | 0.98x | 0.56x | 0.69x | 2.42x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 7M | 7M | 0 | 6.75M | 8.09M | 450.49K | 26.39K | 10.1K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 4.44M | 140.15K | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 1.76K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 3.65M | 310.35K | 26.39K | 10.1K |
| Total Liabilities | 7.16M | 7.44M | 7.3M | 7.01M | 24.58M | 9.91M | 3.36M | 2.22M |
| Total Debt | 0 | 0 | 2.62M | 4.27M | 17.21M | 4.43M | 854.7K | 301.66K |
| Net Debt | -2.09M | -1.66M | 2.28M | 4.08M | 4.95M | 1.29M | -268.91K | -3.2M |
| Debt / Equity | - | - | - | - | - | - | - | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | -0.62x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -1.62x | -15.34x | -221.16x | -30.28x | -5.22x |
| Total Equity | 195.27M | 197.39M | -6.68M | -6.66M | -8.16M | -4.03M | -651.27K | 3.38M |
| Equity Growth % | - | 0.01% | -1.03% | 0% | -0.23% | 0.51% | 0.84% | 6.19% |
| Book Value per Share | 32.63 | 32.87 | -1.10 | -1.05 | -97.10 | -22.40 | -0.29 | 1.93 |
| Total Shareholders' Equity | 195.27M | 197.39M | -6.68M | -6.44M | -7.88M | -3.71M | -322.86K | 3.71M |
| Common Stock | 673 | 604 | 5.99K | 1.58K | 124 | 53 | 315 | 136 |
| Retained Earnings | -31.19K | 2.09M | -56.02M | -55.96M | -85.85M | -110.93M | -121.56M | -129.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -673 | -604 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | -217.63K | -279.81K | -315.21K | -328.41K | -328.48K |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -251.83K | -1.24M | 10.99M | -1.25M | -8.24M | -17.89M | -10.78M | -7.5T |
| Operating CF Margin % | - | - | 6.23% | -0.32% | -2.33% | -7.09% | -4.83% | -999999% |
| Operating CF Growth % | - | -3.92% | 9.88% | -1.11% | -5.61% | -1.17% | 0.4% | -695983.46% |
| Net Income | -31.19K | -1.34M | 365.95K | -160.88K | -29.15M | -24.21M | -10.63M | -7.99M |
| Depreciation & Amortization | 0 | 0 | 0 | 201 | 151 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 178.68K | 121.76K | 1.07M | 879.16K | 110.72B |
| Deferred Taxes | 0 | 1.76K | -1.76K | -2.45M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -231.1K | -317.21K | 8.17M | 997.46K | 22.09M | -233.42K | -85.79K | -7.61T |
| Working Capital Changes | -101.5K | 273.13K | 2.46M | 185.1K | -1.3M | 5.48M | -947.08K | -851.25K |
| Change in Receivables | 0 | -170.53K | 0 | 173.55K | -441.72K | 164.9K | 179.26K | -26.55K |
| Change in Inventory | 0 | 0 | 0 | -173.55K | 0 | 0 | 0 | 0 |
| Change in Payables | 111.96K | 317.28K | 0 | 1.18M | -1.42M | 2.64M | -1.23M | -578.93K |
| Cash from Investing | -200M | 838.59K | -566.29K | 183.4M | 0 | 4.5K | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | 0% | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 838.59K | 0 | 183.4M | 0 | 4.5K | 0 | 0 |
| Cash from Financing | 202.34M | -32K | -11.03M | 1.1M | 20.31M | 8.77M | 8.76M | 9.88T |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -290M |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 0 | 0 | -225.68K | -1.14M | -899.55K | 9.88T |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -251.83K | -1.24M | 10.99M | -1.25M | -8.24M | -17.89M | -10.78M | -7.5T |
| FCF Margin % | - | - | 6.23% | -0.32% | -2.33% | -7.09% | -4.83% | -999999% |
| FCF Growth % | - | -3.92% | 9.88% | -1.11% | -5.61% | -1.17% | 0.4% | -695983.46% |
| FCF per Share | -0.04 | -0.21 | 1.81 | -0.20 | -98.10 | -99.41 | -4.76 | -999999.00 |
| FCF Conversion (FCF/Net Income) | 8.07x | 0.92x | -1.09x | -21.97x | 0.28x | 0.74x | 1.02x | 939363.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 1.6K | 1.6K | 1.6K | 3.2K | 3.2K |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -0.02% | -0.68% | -10.59% | - | - | - | - | -585.41% |
| Return on Invested Capital (ROIC) | -0.06% | -0.37% | -6.72% | - | - | - | - | - |
| Gross Margin | - | - | -92.88% | 99.99% | 100% | -686.08% | -240.12% | -38.57% |
| Net Margin | - | - | -572.7% | 1.44% | -823.62% | -957.93% | -475.71% | -153.3% |
| Debt / Equity | - | - | - | - | - | - | - | 0.09x |
| Interest Coverage | - | - | - | -1.62x | -15.34x | -221.16x | -30.28x | -5.22x |
| FCF Conversion | 8.07x | 0.92x | -1.09x | -21.97x | 0.28x | 0.74x | 1.02x | 939363.97x |
| Revenue Growth | - | - | - | 122.86% | -10.18% | -28.54% | -11.59% | 133.53% |
| 2022 | 2023 | |
|---|---|---|
| M P A R | 2.01M | - |
| M P A R Growth | - | - |
Ensysce Biosciences, Inc. (ENSC) reported $4.5M in revenue for fiscal year 2024.
Ensysce Biosciences, Inc. (ENSC) grew revenue by 133.5% over the past year. This is strong growth.
Ensysce Biosciences, Inc. (ENSC) reported a net loss of $11.0M for fiscal year 2024.
Yes, Ensysce Biosciences, Inc. (ENSC) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Ensysce Biosciences, Inc. (ENSC) has a return on equity (ROE) of -585.4%. Negative ROE indicates the company is unprofitable.
Ensysce Biosciences, Inc. (ENSC) had negative free cash flow of $7.2M in fiscal year 2024, likely due to heavy capital investments.